NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) in the United States District Court for the Middle District of Tennessee on behalf of all persons and entities who purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the “Class Period”) ...

SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.For more information, submit a form, email attorney Aar ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee on behalf of all persons or entities who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance Therapeutics” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or m ...

ATLANTA, Jan. 06, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about Revance’s business, operations, and prospects, including allegations that: (i) Revance was in material breach of its distribution agreement with Teoxane SA; (ii) the foregoing subjected Revance to ...

Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (Nasdaq: RVNC) to acquire Revance for $3.60 per share in cash. Teoxane beneficially owns 6.2% of the outstanding shares of common stock of Revance. Teoxane's proposal provides a 16% premium over the $3.10 per share price in Rev ...

Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Hyaluronic Acid Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.The hyaluronic acid market has witnessed significant growth in recent years, driven by its diverse applications in industries such as pharmaceuticals, cosmetics, and food. Hyaluronic acid, a naturally occurring polysaccharide, is known for its remarkable ability to retain mois ...

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.71%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.36, delivering a surprise of 25%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or o ...

Exhibit 99.1 REVANCE Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update – On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the deadline upon which the tender offer must commence to November 12, 2024. The tender offer has not yet commenced. – Revance entered into an amendment to the Exclusive Distribution Agreement with Teoxane for the distributi ...

Revance Therapeutics, Inc. (RVNC) has been on a downward spiral lately with significant selling pressure. After declining 18% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting wh ...